Skip to content

Clinical observation of remazolam besylate combined with hydromorphone hydrochloride in elderly patients during induction of general anesthesia

Clinical observation of remazolam besylate combined with hydromorphone hydrochloride in elderly patients during induction of general anesthesia

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074907
Enrollment
Unknown
Registered
2023-08-20
Start date
2023-08-20
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly patients scheduled for general anesthesia

Interventions

Group A:Patients in group A were given the investigational drugs imazolam besylate, hydromorphone hydrochloride, and rocuronium bromide according to the trial protocol.
Group B:Patients in group B were given experimental drugs Sufentanil, propofol and rocuronium bromide according to the trial protocol.

Sponsors

People 's Hospital Of Ningjin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 79 Years

Inclusion criteria

Inclusion criteria: (1) Elderly patients scheduled for general anesthesia; (2) Patients aged 65-79 years, male or female; (3) Body mass index (BMI) 18.5 ~ 30 kg/m2; (4) American Society of Anesthesiologists (ASA) grade I ~ III; (5) Voluntary participation and signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients who refused to participate in the trial; (2) Patients with a history of severe heart, brain, lung, liver, kidney and metabolic diseases; (3) Patients with a history of abnormal surgical anesthesia recovery; (4) Electrocardiogram showed heart rate 180 mmHg and/or diastolic blood pressure > 110 mmHg, or patients with hypotension < 90/60 mmHg; (7) Patients with neuromuscular system diseases and mental illness; (8) Patients with anemia; (9) Suspected abuse of narcotic analgesics or sedatives; (10) Patients who are predicted to have or have had difficult airways; (11) Patients known to be allergic to emulsion and opioids; (12) Patients who are uncooperative and unable to communicate.

Design outcomes

Primary

MeasureTime frame
Systolic blood pressure;Diastolic;Mean arterial pressure;Heart Rate;

Secondary

MeasureTime frame
Cardiac Output;Stroke Volume;Peripheral vascular resistance;Respiratory rate;Oxygen saturation;Bispectral index;Anesthesia induction time;Time from first dose to emergence;Time from last drug addition to emergence;Orientation recovery time;

Countries

China

Contacts

Public ContactLiu Yuan

People 's Hospital Of Ningjin

liuyuan214432@163.com+86 152 0697 9158

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026